Barclays
STSA

Barclays’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Barclays’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,841
Closed -$11.1K – 5288
2023
Q1 		$11.1K Sell
15,841
-52
-0.3% -$48 ﹤0.01% 4742
2022
Q4 		$14.3K Sell
15,893
-203,009
-93% -$588K ﹤0.01% 4872
2022
Q3 		$1.31M Buy
218,902
+16,424
+8% +$93.1K ﹤0.01% 2029
2022
Q2 		$838K Hold
202,478
– – ﹤0.01% 2494
2022
Q1 		$769K Buy
+202,478
New +$912K ﹤0.01% 2597

Barclays's STSA Position: Q2 2023 in Review

Barclays sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 15,841 shares — an estimated $11.1K sold.

Barclays first reported a position in STSA in Q1 2022 and held it in 5 quarters. The position peaked at $1.31M in Q3 2022. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

  • Barclays reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 15,841 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $11.1K.
  • Barclays first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
  • Barclays's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $1.31M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.